NASDAQ:CCXI - ChemoCentryx Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$12.25 +0.22 (+1.83 %)
(As of 06/25/2018 03:25 PM ET)
Previous Close$12.22
Today's Range$12.03 - $12.45
52-Week Range$5.42 - $15.08
Volume12,629 shs
Average Volume316,212 shs
Market Capitalization$591.27 million
P/E Ratio33.42
Dividend YieldN/A
Beta1.66
ChemoCentryx logoChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900

Debt

Debt-to-Equity Ratio0.18
Current Ratio1.95
Quick Ratio1.95

Price-To-Earnings

Trailing P/E Ratio33.42
Forward P/E Ratio-12.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$82.50 million
Price / Sales7.30
Cash Flow$0.3815 per share
Price / Cash32.11
Book Value$1.63 per share
Price / Book7.52

Profitability

EPS (Most Recent Fiscal Year)$0.36
Net IncomeN/A
Net MarginsN/A
Return on Equity31.56%
Return on Assets9.03%

Miscellaneous

Employees66
Outstanding Shares49,150,000

The Truth About Cryptocurrencies

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How were ChemoCentryx's earnings last quarter?

ChemoCentryx Inc (NASDAQ:CCXI) released its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.04. The biopharmaceutical company earned $9.55 million during the quarter, compared to analyst estimates of $9.10 million. View ChemoCentryx's Earnings History.

What price target have analysts set for CCXI?

4 brokers have issued 12 month target prices for ChemoCentryx's stock. Their predictions range from $16.00 to $20.00. On average, they expect ChemoCentryx's stock price to reach $17.6667 in the next year. View Analyst Ratings for ChemoCentryx.

What are Wall Street analysts saying about ChemoCentryx stock?

Here are some recent quotes from research analysts about ChemoCentryx stock:
  • 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (5/16/2018)
  • 2. Cowen Inc analysts commented, "ChemoCentryx reported Q2 financials, including a net loss of $9.2MM and a June 30." (8/8/2017)

Who are some of ChemoCentryx's key competitors?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the folowing people:
  • Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 59)
  • Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 55)
  • Mr. William C. Fairey Jr., Exec. VP & COO (Age 53)
  • Dr. Rajinder Singh, Sr. VP of Research (Age 51)
  • Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 65)

Has ChemoCentryx been receiving favorable news coverage?

Media coverage about CCXI stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ChemoCentryx earned a coverage optimism score of 0.08 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 45.95 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by many different of retail and institutional investors. Top institutional investors include BVF Inc. IL (14.68%), BlackRock Inc. (5.23%), Wasatch Advisors Inc. (4.86%), Franklin Resources Inc. (3.44%), Farallon Capital Management LLC (1.93%) and Carmignac Gestion (0.79%). Company insiders that own ChemoCentryx stock include Markus J Cappel, Petrus Bekker, Roger C Lucas, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.

Which major investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Franklin Resources Inc., BlackRock Inc., Spark Investment Management LLC, Unterberg Capital LLC, Trexquant Investment LP, Federated Investors Inc. PA and Landscape Capital Management L.L.C.. Company insiders that have sold ChemoCentryx company stock in the last year include Markus J Cappel, Petrus Bekker, Roger C Lucas, Susan M Kanaya and Thomas J Schall. View Insider Buying and Selling for ChemoCentryx.

Which major investors are buying ChemoCentryx stock?

CCXI stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Carmignac Gestion, PNC Financial Services Group Inc., Wasatch Advisors Inc., Millennium Management LLC, JPMorgan Chase & Co., Alps Advisors Inc. and American Century Companies Inc.. View Insider Buying and Selling for ChemoCentryx.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $12.31.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $591.27 million and generates $82.50 million in revenue each year. ChemoCentryx employs 66 workers across the globe.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]


MarketBeat Community Rating for ChemoCentryx (CCXI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  278
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.